Low-Dose Naltrexone (LDN): The Cheap Off-Label Drug People Swear By, and What the Evidence Says

Naltrexone at its normal dose blocks opioid receptors and is used in addiction treatment. At about a tenth of that dose, something different seems to happen, and a large community of people with chronic pain and inflammatory conditions credit "LDN" with giving them their lives back. It is cheap, well tolerated and taken by a growing number of people for conditions it was never approved to treat. The evidence is genuinely promising and genuinely thin at the same time. Here is the honest picture.

In short

• Low-dose naltrexone (LDN) means roughly 1.5 to 4.5 mg a day, far below the standard addiction dose.
• It is used off-label for fibromyalgia, chronic pain, autoimmune conditions, ME/CFS and long COVID, among others.
• The likely mechanism is anti-inflammatory action in the nervous system, not the opioid-blocking effect it is known for.
• It is cheap and generally well tolerated, which is part of its appeal.
• The evidence is early and mixed: encouraging small studies, but few large, high-quality trials. Promising is not the same as proven.

What is LDN and how might it work?

At low doses, naltrexone appears to act as an anti-inflammatory in the central nervous system by calming the brain's immune cells, an effect separate from the opioid receptors it blocks at high doses. Research summarised in this PMC review suggests low-dose naltrexone quiets microglia, the immune cells of the brain and spinal cord, which could dial down the kind of nervous-system inflammation implicated in chronic pain. That mechanism is still being worked out, but it explains why a drug known for addiction treatment would help conditions that have nothing to do with opioids. The full drug profile is on our naltrexone page.

Which conditions is it used for?

A long and growing list, led by fibromyalgia, but including chronic pain, Crohn's disease, multiple sclerosis, ME/CFS and long COVID. Fibromyalgia has the most study attention, with several small trials suggesting benefit for pain. Beyond it, people use LDN for multiple sclerosis, inflammatory bowel disease, complex regional pain syndrome and post-viral illness. The common thread is chronic, inflammation-linked conditions that conventional treatment often handles poorly, which is exactly the space where people go looking for something else. You can see related options on our autoimmune care page.

Does the evidence actually support it?

It is genuinely encouraging but still early, with small studies and few large, replicated trials, so it should be read as promising rather than proven. A systematic review of LDN for fibromyalgia, collected in this PMC review, found signals of benefit but flagged small sample sizes and a need for better trials. That pattern repeats across its other uses: hopeful case series and small studies, not the large randomised trials that settle a question. This is the honest tension. Many people report real improvement, and the science has not yet caught up to confirm or refute it at scale. Neither the enthusiasts nor the sceptics can claim the matter is closed.

Why is it so popular if the evidence is thin?

Because it is inexpensive, well tolerated, and offered as an option for conditions where standard treatment often disappoints, so the risk-to-try feels low. When someone has had fibromyalgia or long COVID for years with little relief, a cheap daily tablet with a mild side-effect profile is an easy thing to try. Vivid personal accounts spread through patient communities and advocacy groups, which amplifies interest faster than trials can test it. That popularity is understandable, but it is not itself evidence, and it is worth keeping the two separate.

Is it safe to try?

It has a favourable side-effect profile, but it is still a prescription medicine that interacts with opioids, so it needs a doctor's involvement. The most common side effects are mild, such as vivid dreams or sleep changes early on. The important interaction is with opioid painkillers: because naltrexone blocks opioid receptors, it can interfere with them and, at full dose, precipitate withdrawal, so anyone using opioid medicines must have this managed by a prescriber. It is compounded to the low dose by a pharmacy, which is another reason it runs through professionals rather than being self-sourced.

The bottom line

Low-dose naltrexone is a real example of an old, cheap drug finding a promising second life, with a plausible mechanism and a devoted following. It is also a reminder that promising and proven are different words. If you are considering it for a stubborn chronic condition, it is reasonable to raise with a clinician who can weigh it against your other medicines, especially any opioids, and set expectations honestly.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.